## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL						
OMB Number:	3235-0287						
Estimated average burden							
nours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)															
1. Name and Address of Reporting Person * MANAK MARK					2. Issuer Name and Ticker or Trading Symbol BOSTON BIOMEDICA INC [BBII]							5. Re	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) 200 STANLEY PLACE				3. Date of Earliest Transaction (Month/Day/Year) 09/03/2003								X	X Officer (give title below) Other (specify below)  Senior Vice President				v)
(Street) LAUREL, MD 20707				4. If Amendment, Date Original Filed(Month/Day/Year)								_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(Cit	<u> </u>	(State)	(Zip)	Table I - Non-Derivative Securities Acqu					Acquired,	lired, Disposed of, or Beneficially Owned							
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if		Coc (Ins	tr. 8)	(A) (Inst	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)  (A) or		(Ins	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership Form: Direct (D) or Indirect (I)	Beneficial Ownership		
Common	Stock		09/03/2003					M V	518		\$	Price 24,:	507			(Instr. 4)	
Common	Stock											4,00	00			[	Daughter
Reminder:	Report on a	separate line for each						Pers	ons aine disp	l in this lays a c	forn urre	n are not i ntly valid	required OMB co	of informato respon	d unless th		474 (9-02)
								ts, options,					neu				
Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	Execution Date, if	f Transaction of Code D (Instr. 8) S A (A D O) (I			rative rities ired r osed )	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownersh Form of Derivativ Security: Direct (I or Indire	(Instr. 4)	
				Code	V	(A)	(D)	Date Exercisabl	e	Expiration Date	on	Title	Amount or Number of Shares				
Option (Right to Buy)	\$ 3.25							02/28/19	97 <mark>(1)</mark>	02/28/2	006	Commor Stock	2,500		2,500	D	
Option (Right to	\$ 3.25							04/14/19	99 <u>(1)</u>	04/14/2	2008	Commor Stock	6,000		6,000	D	
Buy)	Ψ 3.23																
Buy) Option (Right to Buy)								02/03/20	01(1)	02/03/2	010	Commor Stock	5,000		5,000	D	
Option (Right to	\$ 4							02/03/200					5,000		5,000	D D	

#### **Reporting Owners**

D	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MANAK MARK 200 STANLEY PLACE LAUREL, MD 20707			Senior Vice President			

### **Signatures**

Mark M. Manak	09/17/2003	
**Signature of Reporting	Date	

Person

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person,  $\emph{see}$  Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Table II, Column 6 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7 . The options become exercisable in 25 percent annual increments beginning on the date set forth in Table II, Column 6.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.